What it sells
RNA medicines for liver diseases
Business model breakdown
Buyer: who owns the budget?
UnverifiedPharma R&D / business development heads (e.g. GSK AI/ML, Boehringer Ingelheim cardiometabolic research quoted as partners).
Trigger: what makes them buy now?
Need for validated liver disease targets and human-derived datasets; 1.5m people die globally of liver disease with limited treatments.
Workflow: what inputs become what output?
AI over proprietary gene perturbation atlases and patient disease atlases to predict targets, validated in human models (perfused livers, diseased tissue slices, primary cells), then in-house RNA therapy making; pipeline led by development candidate OB-220 for significant fibrosis.
Economics: what it saves and how it charges
Two routes: internal RNA pipeline and partnerships; a quoted commentator says the GSK deals show disease-specific datasets are valued like discovery IP. Deal terms not disclosed.
Distribution: how it reaches customers
Partnership deals with large pharma (GSK research completed Nov 2025 per news page); no self-serve.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2020 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.